Doximity is the largest professional medical network in the United States, with over 3 million registered members representing approximately 85% of US physicians, according to its Q3 FY2026 earnings call. The company expects approximately $643 million in FY2026 revenue, mostly from pharmaceutical and health system advertising.
Its AI product changed materially after the August 2025 Pathway Medical acquisition ($63 million). Pathway brought a large structured medical dataset spanning guidelines, peer-reviewed drug monographs, and landmark trials. Within seven weeks, Doximity integrated Pathway data and models into DoxGPT. The result was a shift from a documentation-focused assistant toward a broader clinical reference experience, including instant answers across 3,200+ drug monographs with dosing and interaction data.
Doximity also launched PeerCheck, a physician-led AI review program with over 10,000 medical experts, co-chaired by Eric Topol and former US Surgeon General Regina Benjamin. PeerCheck-certified answers link to reviewing physician profiles. In a company-published evaluation of over 1,300 physicians, DoxGPT was preferred over OpenEvidence and other competitors at more than twice the rate of the next closest option.
Adoption is substantial: more than 300,000 unique clinicians used Doximity AI tools in Q3 FY2026, and over 100 health systems have enterprise access. The tradeoff is product focus. The app still centers on networking and communications, so the clinical workflow can feel secondary compared with dedicated CDS products.